J.H. Hare & Associates, Ltd. – Trademark Portfolio
Entity Type: 03
J.H. Hare & Associates, Ltd. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 29 (Meats & Processed Foods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include HYPER-EGG and IMMUNADE NATURE'S IMMUNITY FOOD. The owner is based in Winnipeg, MB.
1-270 Roslyn Road
Winnipeg, MB R3L0H3 , CA
Showing of trademarks Trademarks
Trademark Classifications
J.H. Hare & Associates, Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits
Frequently Asked Questions
How many trademarks does J.H. Hare & Associates, Ltd. have?
J.H. Hare & Associates, Ltd. has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 2 cancelled.
What trademark classes does J.H. Hare & Associates, Ltd. file in?
J.H. Hare & Associates, Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 29 (Meats & Processed Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are J.H. Hare & Associates, Ltd.'s most well-known trademarks?
J.H. Hare & Associates, Ltd.'s registered trademark portfolio includes well-known marks such as HYPER-EGG and IMMUNADE NATURE'S IMMUNITY FOOD. These are among 2 currently registered trademarks in the portfolio.
What is J.H. Hare & Associates, Ltd.'s trademark registration success rate?
J.H. Hare & Associates, Ltd. has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.